Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 8,745 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $52.47, for a total transaction of $458,850.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of GHDX stock opened at $51.13 on Wednesday. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of 48.70 and a beta of 1.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.67 and a current ratio of 5.67. Genomic Health, Inc. has a 52 week low of $48.00 and a 52 week high of $92.18.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The company had revenue of $108.80 million for the quarter, compared to analyst estimates of $106.75 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The company’s quarterly revenue was up 17.5% compared to the same quarter last year. Research analysts predict that Genomic Health, Inc. will post 1.44 earnings per share for the current year.
Several analysts have commented on the stock. BidaskClub lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $85.00 price objective (down previously from $95.00) on shares of Genomic Health in a research report on Wednesday, May 8th. Deutsche Bank lowered their price objective on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a research report on Thursday, May 30th. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $69.00 price objective (down previously from $97.00) on shares of Genomic Health in a research report on Thursday, May 9th. Finally, ValuEngine lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. Eleven analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Genomic Health presently has a consensus rating of “Hold” and an average target price of $62.63.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Further Reading: Growth and Income Funds
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.